MENU

Can Telomir Pharmaceuticals (TELO) Stock Reach $4.00?

A.I.Advisor
published price charts
A.I.Advisor
Nov 10, 2026

Can Telomir Pharmaceuticals (TELO) Stock Reach $4.00?

Key Takeaways

  • The $4.00 central target reflects a single research firm's objective, not a multi-analyst consensus, and implies a very large move from current levels.
  • Shares of Telomir Pharmaceuticals, Inc. (TELO) recently traded near $0.71, meaning the target sits roughly 463% above the latest verified price.
  • The only current, attributable analyst price target is $4.00, set by Maxim Group analyst Jason McCarthy on September 17, 2026 alongside a Buy rating.
  • Supporting factors include an FDA-cleared IND (Investigational New Drug) application for the lead candidate in triple-negative breast cancer and encouraging early preclinical data.
  • Principal risks are the company's early-stage status, absence of product revenue, ongoing cash burn, and the extreme volatility typical of micro-cap biotech stocks.
  • Investors can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • Those exploring broader market ideas may also want to review Trending AI Robots.

How the $4.00 Target Was Established

Telomir Pharmaceuticals is a clinical-stage biotechnology company headquartered in Miami, Florida, focused on small-molecule therapeutics for aging-related conditions and oncology. Its lead asset, Telomir-1 (also referenced as Telomir-Zn), is an oral small molecule designed to regulate intracellular metal-ion balance. Because TELO has very thin sell-side coverage, there is no meaningful multi-analyst consensus to average.

The $4.00 figure comes from publicly reported analyst commentary rather than an aggregate. Maxim Group's Jason McCarthy initiated coverage on September 17, 2026 with a Buy rating and a $4.00 price target, citing the company's approach to upstream biological drivers of disease. This is the only current, individually attributable analyst price target. An earlier, higher target around $15 from roughly a year ago appears to have lapsed, and some data aggregators still surface stale figures near $15.50 that no longer reflect active coverage. The $4.00 objective should therefore be read as a single-firm view, not an analyst consensus.

Current Market Position and Path Toward the Target

Shares recently closed near $0.71, toward the lower end of a 52-week range spanning roughly $0.67 to $1.58. Reaching $4.00 would require a gain of about 463% from that level — a very large move even by the standards of speculative biotech. With a market capitalization of roughly $50 million and no product revenue, TELO trades on the perceived value of its pipeline rather than on current fundamentals, so the gap between the current price and the $4.00 objective is essentially a statement about clinical and regulatory execution rather than near-term earnings.

The path toward the target would most plausibly run through positive clinical readouts, further regulatory milestones, and a re-rating of the shares as the company converts preclinical promise into late-stage data. Each step carries substantial binary risk.

What Could Support a Move Toward the Target

The clearest fundamental catalyst is regulatory progress. The company has received FDA clearance for an IND application to begin a clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC), a difficult-to-treat indication with high unmet need. Earlier preclinical work announced in 2025 demonstrated cellular-protective activity in human progeria cell lines, and the pipeline also addresses conditions such as Wilson's disease and age-related inflammatory disease.

A successful early clinical readout, additional IND clearances, or a well-received financing or partnership could each support a re-rating. Because the shares are thinly covered and lightly held by institutions, a single positive catalyst can produce outsized moves in either direction.

What Could Prevent the Target From Being Reached

The risks are substantial. The company is clinical-stage with no marketed products, reporting negative EPS (earnings per share) of about -$1.11 over the trailing twelve months and a modest cash balance reported near $5.2 million in the latest quarter. Continued cash burn will likely require future capital raises, which can dilute shareholders and pressure the stock.

Clinical trials in oncology and rare disease frequently fail or are delayed, and early preclinical results do not guarantee human efficacy or safety. The shares are also volatile, having fallen sharply from earlier-year levels, and a single $4.00 target provides no confirmation from competing analysts. Any regulatory setback, adverse safety signal, or unfavorable financing would materially undercut the path to $4.00.

Technical Levels and Market Structure

TELO has been in a broad downtrend, trading near the bottom of its 52-week range. The area around $0.67 represents the recent support level, while prior trading near $1.20 and the 52-week high near $1.58 sit well below the $4.00 objective and would likely act as intermediate resistance zones on any sustained recovery. A move toward the target would require the stock to reclaim and hold levels far above where it has traded recently, underscoring how distant the objective is in market-structure terms.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly twelve months, though a single initiating note provides no consensus on timing. Investors should watch for updates on the Telomir-Zn TNBC clinical program, including enrollment and initial data, any additional FDA interactions or IND clearances, quarterly cash and financing disclosures, and any new analyst initiations or target revisions that would broaden the coverage picture. Dilution risk and clinical milestones are the most consequential variables for the price forecast.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly traded, high-volatility name like TELO, such tools can help traders surface opportunities, track positions, and identify changing trends more efficiently than manual scanning. Traders interested in a systematic view of daily momentum may wish to explore the AI Daily Buy/Sell Signals page.

Final Assessment

The question of whether TELO can reach $4.00 hinges less on valuation and more on clinical execution. The $4.00 target, drawn from a single Maxim Group initiation rather than a consensus, implies a very large move of roughly 463% from the recent price near $0.71. The strongest support comes from FDA clearance to advance Telomir-Zn into a triple-negative breast cancer trial and a pipeline aimed at unmet medical needs. The principal obstacles are the company's early stage, negative earnings, ongoing capital needs, and the absence of corroborating analyst coverage. Investors should monitor clinical and regulatory milestones, financing activity, and any broadening of sell-side coverage, while recognizing that micro-cap biotech price targets carry unusually wide uncertainty.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TELO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TELO has been loosely correlated with DMRA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TELO jumps, then DMRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TELO
1D Price
Change %
TELO100%
-0.61%
DMRA - TELO
35%
Loosely correlated
+1.86%
TWST - TELO
33%
Poorly correlated
+3.88%
TNXP - TELO
31%
Poorly correlated
-4.08%
MGX - TELO
31%
Poorly correlated
+0.13%
RXRX - TELO
31%
Poorly correlated
+3.86%
More
Can Telomir Pharmaceuticals (TELO) Stock Reach $4.00?